Nonalcoholic Steatohepatitis: Epidemiology, Screening, Risk Assessment, Diagnosis, and Management

  • Author: Philip N. Newsome, PhD, FRCPE (More Info)
  • Editor In Chief: Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
  • Last Reviewed: 8/23/19 (What's New)

Summary

  • Medical interventions largely prioritize managing coexisting components of the metabolic syndrome
  • Management of Common Comorbidities
    • Both liver and overall health benefit from management of common comorbidities such as dyslipidemia, hypertension, and T2DM
      • The initiation of lipid-lowering pharmacotherapy depends on the patient’s lipid profile and risk factors for atherosclerotic cardiovascular disease[Grundy 2019]
      Bariatric Surgery
        Pharmacologic Management of NASH
          Investigational Agents

          Action required